Anbio Biotechnology is advancing its European market presence with the launch of the AF-100 C, an innovative compact fluorescent immunoassay analyser poised to redefine point-of-care diagnostics. The device, which includes over 70 assays, is designed to significantly enhance the efficacy of healthcare services across the EU, thus improving patient diagnostics and outcomes.
Anbio Biotechnology (Anbio), a frontrunner in the global in vitro diagnostics industry, is delighted to introduce its expansive “Point of Care” product array to the European Union. This launch represents a key milestone for Anbio, facilitating new partnerships with EU distributors and medical institutions, and affirming the company’s commitment to equipping the EU market with the latest diagnostic innovations.
Beyond its renown as a supplier of Covid test kits, Anbio has emerged as a versatile developer and manufacturer of a broad spectrum of diagnostic devices. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” Michael Lau, CEO of Anbio, articulated.
Advanced Analyzer Provides Healthcare Professionals with Over 70 Critical Tests
Anbio’s entry into the EU is led by the AF-100 C analyzer, a sophisticated, single-channel, handheld, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This robust tool, paired with over 70 CE-marked assays for detecting various analytes such as markers of inflammation, diabetes, cancer, hormones, enzymes, and infectious diseases, is set to significantly alter the EU’s clinical diagnostics scene.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau stated. The compact yet highly efficient AF-100 C is suitable for a range of clinical environments, from small healthcare centres to large emergency departments. Its intuitive operation and reliable battery, enabling continuous testing for up to 8 hours, ensure healthcare workers can offer top-tier patient care with exceptional efficiency and precision.
Fast and Accurate Diagnostic Tools to Enhance Patient Care
The wide-ranging FIA series from Anbio, capable of delivering quick results in 3 to 15 minutes, marks a notable innovation in diagnostic technology. With reagents that incorporate RFID chip technology for accuracy and a storage life of up to 24 months at ambient temperature, Anbio is well-prepared to cater to the immediate needs of the European healthcare industry.
As Anbio Biotechnology makes its foray into the EU market, it extends an invitation to distributors and healthcare professionals to explore its novel diagnostic technologies. Committed to enhancing patient care through cost-effective, precise, and reliable diagnostics, Anbio is looking forward to partnerships with healthcare experts throughout the EU.
